New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
07:28 EDTGILDMacroGenics and Gilead enter strategic alliance to develop DART products
MacroGenics announced it has entered into a license agreement with Gilead for the development and commercialization of Dual-Affinity Re-Targeting products directed at up to four undisclosed targets. MacroGenics' DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. Under the terms of the agreement, MacroGenics could receive a total of up to $30M in license fee payments, and up to an additional $85M in pre- clinical milestones across the four DART programs. Gilead has exclusive worldwide rights for three of the programs. For one program, MacroGenics retains development and commercialization rights outside of North America, Europe, Australia and New Zealand, which encompasses multiple major markets including Japan, China, Korea, Brazil, Russia and others. Gilead will fully fund MacroGenics' research activities with respect to the four programs. MacroGenics could also receive up to approximately $1B in clinical, regulatory and commercialization milestone payments if all four programs achieve the requisite milestones.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
March 26, 2015
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TWTR FB KRFT BIDU TSLA CELG NFLX FCAU
05:34 EDTGILDGilead Sovaldi approved in Japan
Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved Sovaldi, a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus, or HCV, infection with or without compensated cirrhosis. Sovaldi is indicated for use in combination with ribavirin, or RBV, for 12 weeks. Sovaldi is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection. Sovaldi is also the first product to be marketed by Gilead in Japan.
March 25, 2015
16:00 EDTGILDOptions Update; March 25, 2015
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA KRFT FB BIDU GPRO V GILD NFLX
March 24, 2015
08:00 EDTGILDGilead shares should be bought on weakness, says Bernstein
Subscribe for More Information
March 23, 2015
16:01 EDTGILDOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
11:45 EDTGILDGilead defended after slide following death of Hep C patient on heart drug
Subscribe for More Information
11:32 EDTGILDStocks with call strike movement; GILD CELG
Gilead (GILD) August 115 call option implied volatility increased 5% to 27, Celgene (CELG) July 140 call option implied volatility increased 3% to 28 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:44 EDTGILDGilead volatility low into FDA hepatitis C drug warning
Subscribe for More Information
08:23 EDTGILDGilead weakness a buying opportunity, says RW Baird
Subscribe for More Information
07:40 EDTGILDGilead weakness on FDA warning would be buying opportunity, says Wells Fargo
Subscribe for More Information
06:08 EDTGILDGilead implied volatility of 23 at lower end of index mean range
Subscribe for More Information
March 22, 2015
15:05 EDTGILDGilead warns after hepatitis C patient taking heart drug dies, Bloomberg says
Gilead said in an e-mailed drug warning to health-care providers on Friday that nine patients taking its hepatitis C drugs Harvoni or Sovaldi along with the heart treatment amiodarone developed abnormally slow heartbeats and one died of cardiac arrest, says Bloomberg. Reference Link
March 20, 2015
16:00 EDTGILDOptions Update; March 20, 2015
Subscribe for More Information
15:02 EDTGILDAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
March 19, 2015
16:01 EDTGILDOptions Update; March 19, 2015
Subscribe for More Information
09:08 EDTGILDNew Gilead HIV drug likely to be approved in mid-2015, says Argus
Subscribe for More Information
March 17, 2015
06:31 EDTGILDStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
16:00 EDTGILDOptions Update; March 16, 2015
Subscribe for More Information
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use